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Regulation by glutathione of drug transport in multidrug-resistant human
lung tumour cell lines overexpressing multidrug resistance-associated
protein
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S_nary Previous studies have shown that multidrug resistance (MDR) in the doxorubicin-selected lung
tumour cel lines COR-L23/R, GLC4'ADR and MOR/R is associated with overexpression of the MRP gene.
In this study we report that resistance to daunorubicin, vincristine and rhodamine 123 can be partially
reversed in these cell lines by exposing the cells to buthionine sulphoximine (BSO), an inhibitor of glutathione
(GSH) synthesis. This effect of BSO on drug resistance was associated with an increased intracellular
accumulation of daunorubicin and rhodamine 123, owing to inhibition of the enhanced drug efflux. In
contrast, the accumulation of daunorubicin was not increased by BSO treatment in a P-glycoprotein (P-gp)-
mediated MDR cell line. BSO treatment (25 FM, 20 h) of the cell lines resulted in 60-80% depletion ofcellular
GSH levels. The effects of BSO on daunorubicin accumulation in the COR-L23/R and GLC4/ADR cells were
associated with cellular GSH depletion. In addition, increase of cellular GSH levels in BSO-treated COR-L23/R
and GLC4/ADR cells as a result of incubation with 5 mM GSH ethyl ester restored the accumulation deficit of
daunorubicin. However, the transport of daunorubicin did not increase the GSH release in any of the cell
lines. These results demonstrate that drug transport in MRP- but not in P-gp-overexpressing MDR tumour
cell lines can be regulated by intracellular GSH levels.
Keywords multidrug resistance; multidrug resistance-associated protein (MRP); glutathione; buthionine sul-
phoximine (BSO); drug transport
Acquisition of multidrug resistance (MDR) in vitro is often
associated with overexpression of P-glycoprotein (P-gp), the
product of the MDR] gene. P-gp functions as an efflux pump
for cytotoxic drugs, such as anthracyclines and vinca
alkaloids, reducing their cytoplasmic concentration and,
hence, toxicity (Gottesman and Pastan, 1993). We and other
groups have characterised cell lines which show the MDR
phenotype, e.g. broad cross-resistance spectrum and a
decreased drug accumulation, but do not overexpress P-gp
(Zijlstra et al., 1987; Slovak et al., 1988; McGrath et al.,
1989; Kuiper et al., 1990; Coley et al., 1991). Therefore, this
type of MDR is called non-P-gp MDR. As in P-gp-mediated
MDR cells, the drug accumulation deficit is caused by an
enhanced drug efflux, which is energy dependent (Coley et
al., 1991; Versantvoort et al., 1992). Recently, a multidrug
resistance-associated protein (MRP) gene was cloned from
the non-P-gp MDR H69/AR cells (Cole et al., 1992). The
homology of the MRP gene to the ABC superfamily of
active transporters (Cole et al., 1992) and the overexpression
of MRP found in many non-P-gp MDR cell lines (Krish-
namachary and Center, 1993; Slovak et al., 1993; Zaman et
al., 1993; Barrand et al., 1994) strongly suggest that MRP is
the drug transporter, which was functionally shown to be
present, in these cell lines. Indeed, transfection studies with
the MRP gene have now demonstrated induction of MDR in
sensitive cells, and the transfected cells show a decreased
drug accumulation owing to an enhanced drug efflux (Grant
et al., 1994; Zaman et al., 1994).
P-gp-mediated MDR can be reversed by resistance-
modifying agents such as verapamil, cyclosporin A and PSC-
833. These agents have now entered clinical trials in an
attempt to overcome clinical drug resistance. However, these
resistance modifiers are usually less effective in reversal of
MRP-mediated MDR (Zijlstra et al., 1987; Barrand et al.,
1993). In the search for more effective and more specific
resistance-modifying agents for non-P-gp MDR, we have
previously reported that the isoflavonoid genistein increases
daunorubicin (DNR) accumulation in several non-P-gp but
not in P-gp MDR cell lines (Versantvoort et al., 1993).
Although the toxicity of genistein limits its use as a resistance
modifier, it can be used to discriminate between P-gp- and
MRP-mediated DNR accumulation deficits.
Most of the well-characterised non-P-gp MDR cells have
been selected for resistance to doxorubicin (Twentyman et
al., 1986; Zijlstra et al., 1987; Slovak et al., 1988; Kuiper et
al., 1990). Selection in doxorubicin may induce a variety of
resistance mechanisms, including a decreased drug accumula-
tion caused by overexpression of P-gp or MRP, a reduced
DNA topoisomerase II activity and a more effective
detoxification of doxorubicin and/or doxorubicin-induced
radicals by glutathione (GSH) (Gottesman and Pastan, 1993;
Tew, 1994). Several reports have demonstrated that elevated
levels of GSH, together with increased activities of
glutathione S-transferase (GST) or peroxidase, may protect
cells from cytotoxic drugs such as melphalan, platinum com-
pounds and anthracyclines (reviewed in Tew, 1994). Potentia-
tion of the cytotoxicity of doxorubicin has been reported in
several P-gp MDR tumour cell lines (Kramer et al., 1988;
Dusre et al., 1989) following GSH depletion by exposure to
buthionine sulphoximine (BSO), a potent inhibitor of GSH
synthesis. The decreased accumulation of doxorubicin was
not affected by BSO, but an increase in formation of radicals
was measured in GSH-depleted, P-gp-MDR MCF7/ADR
cells, indicating that an increased detoxification by GSH/
GST system caused part of the resistance to doxorubicin
(Dusre et al., 1989).
In early studies on MDR not mediated by P-gp, BSO was
found to increase doxorubicin/daunorubicin (DNR) toxicity
in several non-P-gp MDR cell lines (Lutzky et al., 1989;
Larsson et al., 1991; Meijer et al., 1991). Since GSH and
GST levels were 2-fold increased in the MDR GLC4/ADR
cells compared with the parental cells, it was suggested that
detoxification or doxorubicin by GSH/GST system was an
important factor contributing to doxorubicin resistance in
this non-P-gp MDR cell line (Meijer et al., 1991). In the
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March 1995non-P-gp MDR HL60/AR cells, GSH and GST levels were
decrased compared with the parental cells, but potentiation
of DNR toxicity was accompaned by an increase in cellular
DNR accumulation (Lutzky et al., 1989). In contrast, in the
non-P-gp MDR H69/AR cells the toxicity of doxorubicin
was not potentiated by BSO (Cole et al., 1990). In that study,
however, only 1 9M BSO was used because of the sensitivity
of the resistant cells to BSO, whereas in the other studies
25-50 pM BSO was used. It has now been shown that
GLC4/ADR, HL60/AR and H69/AR cells overexpress the
MRP gene (Cole et al., 1992; Krishnamachary and Center,
1993; Zaman et al., 1993). Thus, BSO is able to reverse
resistance to anthracyclines in some P-gp- and MRP-
mediated MDR cells; however, little is known about its
mechanism and whether BSO could reverse esistance of
other cytotoxic agents involved in the MDR phenotype.
In the present study, we have investigated whether BSO is
a resistance modifier for MRP-mediated MDR. Therefore,
effects ofBSO on the cytotoxicity ofDNR, vincristine (VCR)
and rhodamine 123 (RhI23) were studied in three MRP-
overexpressing, MDR human lung tumour cell lines, COR-
L23/R, GLC4/ADR and MOR/R. In order to develop fur-
ther insght into the mechanism, the effects of BSO on DNR
and Rhl23 transport were examined, and these were related
to changes in cellular GSH levels.
Material and mtod
Chemicals
Daunorubicin hydrochloride and rhodamine 123 were
obtained from Sigma (Poole, Dorset, UK). Vincrisine hyd-
rochloride was from Lederle (Gosport, Hampsire, UK).
[G-3EHDaunorubicin hydrochloride (sp. act. 3.6Cimmol-1)
was obtained from NEN-DuPont de Nemours (Germany).
DL-Buthionime-S,R-sulphoximine, redued form of gluathione,
glutathione ethyl ester and 5,5-dithiobis(2-nitrobenzoic acid)
(DTNB), were all obtained from Sigma.
Cell culture
The human lung cancer cell lines and their doxorubicin-
selected, resistant sublines used in this sudy have been des-
crbed elsewhere: the lrge-cel lung canc cell lnes COR-
L23/P and the MDR sublie COR-L23/R (Twentyman et al.,
1986; Barrand et al., 1993), the small-ell lung carcinoma cell
ie GLC4 and the MDR subie GLC4/ADR (Zijlstra et al.,
1987; Meijer et al., 1991) and the adenocarcinoma line MOR/
P and the MDR sublines MOR/RO.2 and MOR/RO.4 (Bar-
rand et al., 1994). All the cel lines were cultured in RPMI-
1640 medium supplemented with 10% fetal bovine serum
(Sigma) in a humidified incubator in 8% carbon dioxide. T'he
resistant cells were cultured in the presence of doxorubicin
until 2-10 days before experiments. None of the MDR
sublines shows overexpression of the MDR-1 gene (Twenty-
man et al., 1986; Zijlstra et al., 1987; Versantvoort et al.,
1992) but each overexpres the MRP gene (Zaman et al.,
1993; Barrand et al., 1994). Furthermore, a P-gp
overxCpressing small-cell lung carcinoma cell ine, H69/LX4,
and its parental cell line, H69/P, were used (Twentyman et
al., 1986).
Potentiation of the toxicity of DNR, VCR and Rh123 by
BSO was measured as growth inhibition in an MTT assay.
Cells were plated in 96-well plates (Falcon) and exposed to
25 iAM BSO for 20h before addition of DNR, VCR or
Rhl23. Tlen, cells were allowed to grow for 3-4 days and
growth inhibition was determined in an MT assay as des-
cribed by Rhodes and Twentyman (1992).
Cellular drug accwmdation
The accumulation of [3H]DNR and Rh123 was measured as
described previously (Versantvoort et al., 1992; Twentyman
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et al., 1994). Briefly, cells in exponential growth were
harvested and reuspeded (0.2-0.6 x 10' cells ml-') in
20mM Hepes-buffered, RPMI-1640 medium (pH 7.3) without
sodium bcarbonate, but with 10% fetal bovine serum. In
order to examine the effect of BSO on the accumulation of
drugs, cells were cultured in presence of 25DIM BSO for 20 h.
The assay was initiated by addition of [3H]DNR (final con-
centration of [3H]DNR and unlabeled DNR of 0.5 pM) or
Rh123 (0.1jgml' The accumulation ofdrugs was stopped
by addition of ice-cold phosphate-buffered saline (PBS).
After an ice-cold wash with PBS, the uptake of drugs was
analysed by liquid scintillation counting of the radioactivity
(DNR) or by flow cytometry for Rh123 (excitation at 488 um
and emission of fluorescence at 630nm). Values were cor-
rected for amount of cell-associated drugs at time zero at
O-C.
For drug efflux, cels were preincubated with either 25gM
BSO or vehicle for 20h, and subsequently loaded with
[HJDNR or Rh123 for 60min After one wash with ice-cold
PBS, cells were resuspended in p me medium with or
without 25#DM BSO present. At time points thereafter, the
efflux was stopped by another wash with ice-cold PBS and
retention of the drugs in the cells was determined as des-
cribed above.
In order to establish cellular steady-state accumulation of
RhI23, 0.1-0.3 x 10' cells were plated in six-well plates (Fal-
con) and cultured for 2 days. Tben, cells were exposed for
20h to 0.01 pgml-' Rhl23, harvested and the accumulation
of Rh123 was measured by flow cytometry. To determine the
effect of BSO on Rhl23 steady-state accumulation, BSO was
added 4h before the addition of Rhl23 (i.e. incubation with
BSO for a total of 24h).
Glutathione content
Proteins from 0.3-1.5 x 10' cells were precipitated with 2%
trichloroacetic acid (TCA). The cellular GSH content of the
supernatant was determined with FlInan's reagent, 5,5-
dithiobis(2-nitrobenzoic acid), and absorbance was measured
at 412nm (Sedlak and Lindsay, 1968).
Efflunx ofGSH from the cells was measured as described by
Sze et al. (1993). Cells were resuspended (5-l0 x 10'
cellsml-') in 140mM sodium chloride, 5 mM potassium
chloride, 1 mM magnesium chloride, 1 mM calcium chloride,
8 mM disodium hydrogen phosphate, 1.5 mM potassium
dihydrogen phosphate, 1 mgml-' D-glucose and 4mM L-
glutamine and buffered with 20mM Hepes (pH 7.3). Cells
were incubated at 3TC in presnce of 0.2 mM acivic'n, an
inhibitor of T-glutyltransptidase, centrifuged and ali-
quots ofthe supernatant were analysed for thiol content. The
rekase of thiols from cells was linear in time at least up to
1 h.
MRP mRNA andprotein expressin
Compkmentary DNA (cDNA) synthesis and polymrase
chain reaction (PCR) (22 cycles) were carried out as des-
cribed by Barrand et al. (1994). The MRP primers used are
positioned at bases 4005-4024 (sense) and 4756-4776
(antisens). In all expeents amplifiction of a 297 bp frag-
ment of the Prmicroglobulin gene was included as a control
for cDNA recovery. The PCR products were separated by
subsequent eectrophoresis in 2% agarose, transfer to nylon
filters by Southern blottng, hybrdisation with a [3P2CTP
oligo-labelled DNA probe, and finally visuaised by
autoradiography.
Membrane preparations were used to detect MRP by
Western blotting with a rat monoclonal antibody, MRPrI,
recently described by Flens et al. (1994). Membrane proteins
were isolated from a post-nuclei homogenate by centrifuga-
tion at 25000g for 15min at 4C. This 25000g fraction
contained more than 90% of MRP (Versantvoort et al.,
1995).an de - maptbyW
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Potentiation ofdrug toxicity by BSO
Based on the studies of Lutzky et al. (1989) and Meijer et al.
(1991) in which exposure of cells to 25-10(ILfm BSO for
16-48 h reduced cellular GSH content maximaly, we have
used 25 jM BSO (20h exposure) for cytoxicity and drug
accumulation studi. Incubation ofcells with 25 JLM BSO for
20 h was not toxic in any of the cell nes, nor was the
exposure to 25 tm BSO for 6 days in the MUT assay toxic in
any of the resistant cell lines (IC,, value> I0O(um). However,
incubation with 251M BSO for 6 days was toxic in the
parental COR-L23/P and GLC4 cells (IC,O values 15 pM and
11 M vresectively) but not in MOR/P cells (ICo1> 100pm).
Resistance to DNR, VCR and Rh123 and the effects of
BSO on the toxicity of the drugs in the resistant cells are
summarised in Table I. The doxorubicin-seected resistant cell
lnes are all cross-resitant to DNR, VCR and RhI23. The
resistance factors for the three agents were rather similar in
the COR-L23 and MOR nt cels, whereas in the
GLC4/ADR cells resistance to vincristine and especally to
Rh123 was less predominant than resistance to daunorubicin.
The resistance factor for daunorubicn in the GLC4/
ADR cells is probably due in part to reduced levels of
topoisomerase II found in these cells (de Jong et al., 1990).
In all the resisnt cell lines, BSO potentiated the toxicity not
only of the anthracycUie DNR but also of vincistine and
RhI23.
Effect ofBSO on dawnorubicin and rhodamine 123 transport
In order to determine whether the effect of BSO on the
toxicity of drugs in the resistant cells was caused by blocking
the efflux pump present in these cells (Coley et al., 1991;
Versantvoort et al., 1992), we examined the effects ofBSO on
transport of drugs. In Figure 1, uptake of DNR and Rhl23
in COR-L23 cells is shown. ,Steady-state accumulation of
DNR and Rh123 was reached within 30 min and 2 h, respec-
tively, in the reistant cells, whereas it took longer, 2 and
16h, to reach steady-state accumulation in the parental lls.
Preincubation of the reistant COR-L23/R cells with 25 pM
BSO reversed the accumulation deficit for DNR compltely
and for Rhl23 partially. In addition, BSO icreased the
steady-state acnu lation of Rh123 in the parental COR-
L23/P cells to a small extent. However, BSO did not affect
the uptake rate of DNR and Rh123 in the parental lls,
indicating that the passive drug transport was not affected by
BSO.
Data on steady-state acacuulation of DNR and Rhl23 are
summarised for the different cell lines in Table H. A partial
restoration of the drug accumulation deficit by BSO was seen
in all the MRP MDR cell lines. A small but signifit,
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Fugwe 1 Effect of BSO on DNR (a) and Rhl23 (b) accumula-
tion in COR-L23 cells COR-L23/P (crces) and COR-L23/R
(triangles) were incubated in the presen of 25pm BSO (closed
symbols) or vehicle (open symbols) for 20-28 h. Cellular
acuulation of 0.5gm [HDNR (data are means ± sd. from
three experiments, each performed in triplicate) and 0.01 lagml-'
Rhl23 (a representatiVe experiment out of three eperments is
shown) was termined at the time points indicated
Tale H Effect of BSO on daunorubicin and rhodanmne 123
acc ulation
Table I Effect of BSO on drug ance m resstant cell ines
COR-L23/R GLC4/ADR MOtXR/2 MOP4NO.4
Daunorubicin
IC (aM) 0.6 0.2 1.8±0.6 1.2±0.5 1.2±0.4
RP 23 6 87± 24 6.6± 3.3 6.2± 1.6
DMP 11±3 12±6 4.6±2.0 5.1±2.4
Vincristine
ICnq (nm) 44 14 15 ±6 29 ± 11 53 ± 18
RF 32± 8 10±4 4.2± 1.2 8.9± 1.6
DMF 20±5 22±9 12±4 12±3
Rhodamine 123
IC,j agml') 10.1 2.4 1.2 ± 0.5 7.0 ± 3.6 9.8 1.3
RF 21 ±4 2.0±0.6 8.7±2.8 14±7
DMF 18 ± 7 5.7 ± 3.8 3.3 ± 0.3 4.6 0.8
Data shown are mean values ± s.d. from at least three
.ernments a msiswr factor (RF) is expressad as the IC" of
stant cells divid by the IC". of the parental cell bDMF (dose
modfying factor) is expressed as the IC" without BSO treatment
divided by the ICW in the presence of 259Am BSO.
DNR
(pmol per 10 cells)
Control +BSO
Rhl23
(relati to lwoescece in
parent cells)
Control +BSO
COR-L23/P 308 ± 74 350 98- 1 1.35 0.15a
COR-L23/R 104± 25 359± 79a 0.059 ± 0.025 0.71 ± 0.13a
GLC4 123 23 130 22 1 1.10± 0.09
GLC4/ADR 22 10 111±36 0.39±0.07 0.96±0.07"
MOR/P 159 26 291 93' 1 1.41 0.1?
MORIRO.2 59 30 202 58a 0.21 0.02 0.87±0.26
MOR/RO.4 41 15 98 17 0.037 ± 0.007 0.59± 0.14a
H69/P" 187;237 174;263 ND ND
H69/LX4 50±15 44±13 ND ND
(P-gp MDR)
Steady-state acumulatio of 0.5pm [HIDNR (2 h) and
0.01 9gml-I Rhl23 (20h) was measured in BSO-treated cells (25WA,
20h) or under nonmal conditions. Results are exp as
means ± s.d. from at least three experiments. ND, not m ined
'Drug acmulation in the presence of BSO vs control is significantly
different, P<0.05, Student's paired t-test "Data &om two
expments.
Iincrease in steady-state accumulation of DNR and Rh123
was measured in the parental MOR/P and COR-L23/P cells.
However, no effect of BSO was measured in the GLC4 and
H69/P cells. In contrast to the MRP MDR cell lines, BSO
had no effect on the decreased DNR accumulation in P-gp
MDR cell line H69/LX4.
Figure 2 shows that the BSO-induced increase in DNR
and Rhl23 accumulation in the COR-L23/R cells was caused
by inhibition of the enhanced drug efflux. BSO did not affect
the efflux of DNR and Rh123 in the parental COR-L23/P
cells. Inhibition of the enhanced drug efflux was also
observed in the other MRP MDR cell lines (data not shown).
Intracellular glutathione levels
Since BSO is an inhibitor of glutathione synthesis and might
affect drug transport via this pathway, we determined the
effects of BSO treatment on cellular GSH content (Table III).
Basal GSH levels did not correlate with resistance: the COR-
L23/R cells had a lower, the GLC4/ADR cells a higher and
the MOR/R cells a similar GSH content compared with their
parental cell lines. These results are in agreement with
reported data for these cell lines (Meijer et al., 1991; Rhodes
GHad drg tmW by M
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and Twentyman, 1992). Incubation with 25JiM BSO for 20 h
resulted in a similar percentage of GSH depletion in the
resistant and parental cells (Table III).
Correlation between cellular GSH content anddrug transport
To evaluate the effect of GSH depletion by BSO on drug
transport, we studied the concentration- and time-dependent
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Fugwe 3 Dose-response curve of BSO in COR-L23/R and
GLC4/ADR cells. COR-L23/R (open circles) and GLC4/ADR
cells (closed circles) were incubated with various BSO concentra-
tions for 20 h and then examined for (a) cellular GSH content
and (b) DNR accumulation. Results are means ± s.d. of at least
three experiments.
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Ffe 2 Effluxof DNR (a) and Rh123 (b) in the presence of
BSO in COR-L23 cells. COR-L23/P (circles) and COR-L23/R
(triangles) cells were exposed to 25 FM BSO or vehicle for 20 h.
Cells were preloaded with 0.5MM [fH]DNR or 0.1 jigml-' Rh123
for 60 min in the presence (closed symbols) or absence of BSO
(open symbols). Retention of DNR and Rhl23 was measured
after suspending the cells in drug-free medium (open symbols) or
in drug-free medium with 25 ikm BSO (closed symbols). Data are
means ± s.d. of three experiments.
Table m Cellular GSH depletion by BSO
Control 25Sw BSO 25 w BSO
(nmol per itt (nmol per 105 Percentage of
celUs) cells) control
COR-L23/P 19.8 ± 3.0 8.1 ± 2.1 39 ± 12
COR-L23/R 13.5 ± 2.8' 4.1 ± 1.1 31 ± 12
GLC4 5.0±0.7 1.3±0.2 28±5
GLC41ADR 11.5±2.3a 2.3±0.9 18±10
MOR/P 22.3±7.5 5.3±3.2 22± 10
MOR/RO.2 25.1 ± 6.6 4.3 ± 1.5 16 ± 3
MOR/R0.4 19.5 ± 4.0 3.0 ± 0.8 16± 5
Cellular GSH content was determined with Elhnan's substrate in
cells treated with or without 25pum BSO for 20 h. Results are
expressed as means ± s.d. from 5-9 experiments, each performed in
triplicate. aGSH content in resistant cells is significantly different
(P<0.01) from that in parental cells (Student's t-test).
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effects of BSO in the resistant COR-L23/R and GLC4/ADR
cells. A dose-response curve for BSO on GSH depletion and
DNR accumulation is shown in Figure 3. Maximal effects on
GSH depletion and DNR accumulation were measured in the
COR-L23/R and GLC4/ADR cells at 25 yiM and 100gLM
BSO respectively. Intermediate levels of GSH depletion,
caused by incubation with 2.5iLM BSO, resulted in only
partial restoration of the DNR accumulation deficit. Incuba-
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tion of the cells with DNR did not affect the cellular GSH
content (data not shown).
Intermediate levels of GSH depletion could also be
obtained by incubation of the resistant cells for shorter time
periods with 25gM BSO (Figure 4). A gradual decrease in
cellular GSH content up to 50% was measured in the resis-
tant COR-L23/R cells during a 4 h exposure to BSO (Figure
4a). A similar time course effect was measured for the inc-
rease in DNR accumulation (Figure 4b). In contrast to the
rapid fall in the resistant cells, GSH levels were hardly
affected during a 4h incubation with BSO in the parental
COR-L23/P cells. Prolongation of the incubation time with
BSO resulted in similar GSH levels in sensitive and resistant
cells.
The time- and concentration-dependent effects of BSO sug-
gest that the effect of BSO on drug transport in MRP
overexpression cells is caused by cellular GSH depletion. To
exclude further a direct effect of BSO on drug transport, we
increased cellular GSH content in BSO-treated cells with
GSH ethyl ester (Table IV). In contrast to GSH itself,
monoesters of GSH are well transported into cells and hyd-
rolysed intracellularly to GSH (Meister, 1988). Monoesters of
GSH have, therefore, been shown effective in increasng int-
racellular GSH levels even in the presence of BSO (Meister,
1988). As is shown in Table IV, incubation of the cells with
5 mM GSH ethyl ester indeed resulted in elevated cellular
GSH levels. In the BSO-treated resistant cells, an increase in
cellular GSH content was accompanied by a decrease in the
DNR accumulation. No effect of GSH ethyl ester was
measured on DNR accumulation in BSO-treated parental
cells. This result proves that the effect of BSO on drug
transport in MRP MDR cells involves cellular GSH deple-
tion.
-I-
GSH transport
To examine a further interaction between GSH and DNR
transport, we measured the effects of DNR on the release of
GSH into the medium. Since GSH that is released from cells
I I I 1
5 10 15 20
Time (h)
Fugwe 4 Time-dependent effect of BSO in COR-L23 cells. COR-
L23/P (open circles) and COR-L23/R cells (closed circles) were
incubated for various time periods with 25 FM BSO and sampled
for (a) cellular GSH content and (b) DNR acumulation (0.5 jAM,
added during the last 2 h of BSO treatment).
Table V Effect of DNR on GSH release into the medium
GSH release (nmol per 10i cells)
after 60min
Cell line Control 25JiM DNR
COR-L23/P 7.6 1.4 (3) 6.4 ± 1.1 (3)
COR-L23 R 6.1 ± 1.8 (3) 5.3 ± 1.8 (3)
GLC4 1.7 0.5 (2) 1.4± 0.3 (2)
GLC4/ADR 5.3 ± 1.5 (3) 5.3 ± 1.4 (3)
MORIP 4.8 2.4 (4) 3.8 ± 2.1 (3)
MOR/RO.2 8.0 3.1 (4) 7.5 ± 3.7 (3)
MOR/RO.4 11.2 3.0 (5) 10.7 ± 4.1 (4)
GSH release was measured in the medium with Ellman's substrate
following incubation of the cells with or without 25JuM DNR. Data
are mean ± s.d. (number of experiments in parentheses, each
performed in triplicate).
Table IV Modification of BSO effects by GSH ethyl ester
Control 2.5;Im BSO 25JiM BSO
- ester + ester - ester + ester - ester + ester
GSH (nmol per 10i cells)
COR-L23P 19.9 2.4 (3) 26.8 ± 0.9 (3r 6.5 ± 0.5 (3) 14.8 ± 2.6 (3)a
COR-L23 R 15.9 0.6 (3) 25.6±4.1 (3)a 10.1 ± 1.0 (2) 17.1 ± 0.2 (2) 5.1 ± 1.3 (3) 11.7±0.8 (3)3
GLC4 5.4± 0.1 (2) 8.1 ± 1.0 (2) 1.5 ± 0.3 (2) 4.2 ± 0.3 (2)
GLC4/ADR 14.3±2.1 (4) 17.0±0.7 (4) 4.9±0.1 (2) 9.5±2.0 (2) 2.0±0.5 (4) 3.9±0.7 (4)-
Daunorubicin (pmol per 10i cells)
COR-L23/P 350 ± 56 (3) 305 ± 21 (3) 422 ± 77 (3) 427 ± 79 (3)
COR-L23/R 112 27 (3) 66±12 (3) 213± 6 (2) 158±21 (2) 331±48 (3) 260±52 (3)3
GLC4 111 10 (2) 124±8 (2) 126± 7 (2) 130±9 (2)
GLC4/ADR 12±4 (4) 11±5 (4) 31±4 (2) 14±1 (2) 90±26 (4) 54±17 (4)
Cells were incubated with 0, 2.5 or 25 liM BSO for 20 h. Following co-incubation with 5 mm GSH ethyl ester for the last 4h of the
incubation, cellular GSH and DNR content was measured. Data shown are mean ± s.d. of 2-4 experiments (number in parentheses), each
performed in triplicate. 3Value (+ ester) significantly different from value (- ester), P<0.05, Student's paired t-test.
.
l
l
Ican be degraded by y-glutamyltranspeptidase, 0.2 mm
acivicin, an inhibitor, was added to prevent degradation of
GSH (Sze et al., 1993). Release of GSH was similar from
COR-L23 parental and resistant cells, whereas it was in-
creased in the resistant MOR/R and GLC4/ADR cells com-
pared with their parental cells (Table V). If the transport of
DNR were to interact with the transport of GSH, the effects
would be maximal under conditions in which the active DNR
transport is saturated. Previously, we have shown in the
GLC4/ADR cells that the transport of DNR became
saturated at concentrations (in the medium) higher than 5 JIM
and was almost completely saturated at 25 JLM (Versantvoort
et al., 1994). However, 25jiM DNR had no effect on GSH
release in any of the cell lines (Table V).
MRP RNA andprotein expression
It has been reported that oxidative stress, for example caused
by cellular GSH depletion, increases expression of heat shock
proteins, GSTs and other xenobiotic-metabolising enzymes
(Bergelson et al., 1994; Sierra-Rivera et al., 1994). We
examined whether cellular GSH depletion, due to BSO treat-
ment, reduced the expression of MRP RNA and protein and
reversed in this way the accumulation deficit. No effect of
BSO was seen on RNA expression as measured by
RT-PCR, or on protein expression by Western blotting with
the MRPrl antibody (Figure 5).
DiLan
The present study establishes that drug transport in MRP-
overexpressing MDR tumour cells can be regulated by intra-
cellular GSH levels. Depletion of cellular GSH levels in three
MRP-mediated MDR human lung tumour cell lines, follow-
ing exposure of the cells to BSO, results in an increase in
drug accumulation associated with a potentiation of the drug
toxicity. In an abstract by Longhurst et al. (1994), similar
effects of BSO were found for an MRP-overexpressing,
epirubicin-selected CCRF-CEM human leukaemia cell line.
Further, we have shown that the expression of MRP is not
affected by GSH depletion (Figure 5) and that restoration of
cellular GSH levels in BSO-treated MRP-overexpressing cells
reinduces the accumulation deficit of DNR (Table IV). In
contrast to these effects on MRP MDR cell lines, cellular
GSH depletion had no effect on the decreased DNR
accumulation in the P-gp MDR H69/LX4 cell line (Table II).
Thus, these data indicate that drug transport is regulated
differently in MRP- and P-gp-overexpressing cells.
Transfection of the MRP gene in drug-sensitive cells has
now been shown to confer MDR associated with a decreased
accumulatior of drugs (Grant et al., 1994; Zaman et al.,
1994). It is therefore likely that MRP is the drug transporter
which has been shown functionally present in many non-P-
gp-MDR cells (Slovak et al., 1988; McGrath et al., 1989;
Kuiper et al., 1990; Coley et al., 1991). The pharmacological
properties of drug transport in MRP- and P-gp-overexpres-
sing cell lines show very similar characteristics (Broxterman
and Versantvoort, 1995). Most of the drugs that are trans-
ported by P-gp (for example doxorubicin, DNR, VCR, VP-
16 and Rhl23), have now been reported to be transported in
MRP-overexpressing cell lines (Slovak et al., 1988; Versant-
voort et al., 1992. 1993; Twentyman et al., 1994). The
accumulation of drugs is decreased due to an enhanced,
energy-dependent efflux from the cells, and we have demon-
strated that the transport of DNR in the MRP-overexpres-
sing GLC4/ADR cells is saturable (Versantvoort et al., 1994)
with an apparent K,, of 1.4 gM which is similar to the K,,, of
DNR transport found in P-gp MDR cell lines (Spoelstra et
al., 1992). Nevertheless, there are important differences
between MRP and P-gp in the modulation of the drug
transport by resistance modifiers. Cyclosporin A and PSC-
833, effective resistance-modifying agents for P-gp-mediated
MDR, were shown to be less potent in reversing resistance in
GSH anddrugbapo by N
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Fugwe 5 RNA and protein expression of MRP. (a) MRP RNA
expression was determined by RT-PCR as described in the
Materials and methods section. (b) Expression of the 190 kDa
product ofthe MRP gene was measured by Western blotting with
monoclonal antibody MRPrl.
the COR-L23 R cells (Barrand et al., 1993). In addition,
Zaman et al. (1994) reported that cyclosponrn A could not
reverse the DNR accumulation deficit in the MRP-
transfected cells. In contrast, we have shown that the
isoflavonoid genistein increases DNR accumulation in several
non-P-gp MDR cells but not in P-gp MDR cells (Versant-
voort et al., 1993). It was shown in the GLC4/ADR cells that
gemstein inhibited the DNR transport by competition with
DNR (Versantvoort et al., 1994), again indicating a different
handling of the drugs by MRP and P-gp.
Interestingly, Jedlitschky et al. (1994) and Miller et al.
(1994) have found that transport of leukotriene C4 (LTC4)
and S-dinitrophenylglutathione (DNP-GS, glutathione S-
conjugates) is increased in membrane vesicles from MRP-
overexpressing cells as compared with the parental cells.
Photoaffinity studies with [3H]LTC4 labelled the 190 kDa pro-
tein, proving that LTC4 is transported by MRP (JedlitschkyUNHaWdrugbsmpuItby
CHDiVmrstoWt eta
et al., 1994). Thus, a physiological function ofMRP might be
the transport of organic anions such as the leukotrienes
conjugated to GSH or cysteine (Leier et al., 1994).
The findig that MRP transports anionic glutathione S-
conjugates and the present results that clular GSH levels
mgulate drug transport activity have inportant implcations
for our understanding of the mechanism by which cytotoxic
drugs are transported in MRP-overexpressing cells. The most
obvious explanation is that MRP tansports only negatively
charged molecules. In that case, the hydrophobic, mostly
cationic cytotoxic drugs involved in MDR, such as dox-
orubicin, DNR and VCR, should first be metabolised to
become negatively charged, for example by conjugation with
GSH, glucuronate or sulphate groups. This drug-conjugate
might then be a substrate for MRP. The finding presented in
this paper that ceIlular GSH depletion, following BSO treat-
ment, inhibits the enhanced drug efflux (Figure 2) would then
suggest that the drugs are transported in the form of a
glutathione S-conjugate.
Although formation of conjugates with GSH has been
implicated in drug resiance to alkylating agents such as
melphalan and nitrogen mustard, there is no substantial
evidence for conjugation of GSH with any of the MDR
drugs (reviewed in Tew, 1994). After incubation of several
drug-sensitive cells with DNR, no conjugates of DNR could
be detected (de Jong et al., 1992). The lack of evidence for
existence ofglutathione S-conjugates with MDR drugs might
be explained by a possible instability ofthe conjugate. In that
case the conjugate of drugs with glutathione would be, as
soon as it is formed, successively transported out of the cells
and split in the extracellular medium into the single com-
ponents GSH and cytotoxic drug. Transport ofdrugs out of
MRP MDR cells would then give a rise in exracel ar GSH
levels. We have previously masured in GLC4/ADR cells
that, at a DNR concentration of 25AM, about 150pmol
DNR per 10' cells min' is transported (Versantvoort et al.,
1994). If we assume a stoichiometry of one GSH molecule
per molecule DNR transported, incubation of the resistant
cells for one hour with 25gM DNR should then increase the
GSH release into the medium with 9nmol GSH per 10' cells
h-'. However, no inres in GSH release was measured
upon DNR exposure in any of the cell fines (Table V). These
results do not support a model in which drugs are transport-
ed out of MRP MDR cells in the form of glutathione
S-conjugates. Furthermore, MRP-overexpressing ls are not
cross-reistant to alkylating agents (Zijlstra et al., 1987;
Rhodes and Twentyman, 1992), but have a similar cross-
resistanc spectrum as P-gp MDR cells. It has been shown by
drug transport stuies in plasma membrane veicles of P-gp
MDR cels that cytotoxic drugs are transported in free
unconjugated form by P-gp (Hono et al., 1988). These
findings suggest that cytotoxic drugs are transported out of
the MRP-overexpressing cells not in the form of a
glutathione S-conjugate.
Therefore, we would like to interpret the apparent paradox
that overexpression of MRP results in transport ofnegatively
charged moleculs (LTC4, DNP-GS) as well as transport of
neutral or positively charged drugs (VP-16 and DNR), which
has been shown to depend on cellular GSH levels, in terms of
the following two models: (1) MRP is a bifunctional trans-
port protein for anionic glutathione S-conjugates and
cytotoxic drugs or (2) MRP is a glutathione S-conjugate
tansporter and activates an endogenous latent drug trans-
port protein. In the first model, the cytotoxic drugs might
form a ternary complex with glutathione S-conjugates, which
is then transported as the complex by MRP. Cellular GSH
depletion would then result in less complex formation and
would therefore increase the cellular accmulation of drugs.
In this model, modulation of drug transport is not separable
from modulation of transport of glutathione S-conjugates.
Awasthi et al. (1994) showed that transport of doxorubicin
and DNP-GS in membrane vesicles of erythrocytes could
inhibit each other. It was suggested that a 38 kDa protein
was involved in the transport. On the other hand, dox-
orubicin did not inhibit, and vincristine and vinblastin
inhibited only at high concentrations (100piM), the transport
of LTC4 and DNP-GS by MRP (Miiler et al., 1994). Thus,
cytotoxic drugs do not stimulate the transport of glutathione
S-conjugates in MRP-overexpressing cells. Rather than form-
ing a complex with ghltathione S-conjugates, transport of
these compounds might induce a conformational change in
MRP which enables the efflix ofcytotoxic drugs. In that case
modulation of the transport of glutathione S-conjugates, for
example by GSH depletion, would affect the drug transport
activity. The transport of drugs could additionally be
inhibited with resistance modulators by competition for the
drug binding site such as shown for genistein (Versantvoort
et al., 1994).
In the second model, the cytotoxic drugs would be trans-
ported not by MRP but by a latent drug transport protein
present in the cells. MRP might form a membrane-bound
complex with the drug transport protein. The transport of
glutathione S-conjugates would then allow the transport of
drugs through a series of conformational changes. As in the
above described model, inhibition of the glutathione S-
conjugate transport would inhibit the drug transport, but
drug transport could also be inhibited at its drug binding
sites.
In conclusion, our results indicate that transport of drugs
in MRP-overexpressing but not in P-gp-overexpressing MDR
cells can be regulated by cellular GSH levels. In the models
described above we have assumed that GSH depletion
inhibited the drug transport through inhibition of the trans-
port of glutathione S-conjugates by MRP. However, the
possibility that GSH depletion causes a conformational
chang in MRP, which inhibits the transport of drugs, or
activates an inhibitory molecule cannot be excluded. In this
case MRP-mediated glutathione S-conjugate and drug trans-
port can be completely distinct and separable. Further inhibi-
tion studies as well as studies on transport of cytotoxic
agents in insde-out plasma membrane vesicles of MRP-
overpresing cells will provide evidence in which form the
cytotoxic agents are transported and their dependence on
GSH and/or glutathione S-conjugates.
Abbmciatim MDR, multidrug ance; P, Pycoprotein;
MRP, multidrug resistance-asociated protein; GSH, ghutathione;
GST, glutathione S-tansferae; DNR, daunorubicin; VCR, vixcis-
tine; RhI23, rhodamine 123; BSO, Dx-buthionine (SR)-
sulphoximine; LTC4, kukotriene C*; DNP-GS, s-
dinitphenyglutathione
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